glimepiride has been researched along with Urinary Tract Infections in 1 studies
glimepiride: structure given in first source
Urinary Tract Infections: Inflammatory responses of the epithelium of the URINARY TRACT to microbial invasions. They are often bacterial infections with associated BACTERIURIA and PYURIA.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Müller-Wieland, D | 1 |
| Kellerer, M | 1 |
| Cypryk, K | 1 |
| Skripova, D | 1 |
| Rohwedder, K | 1 |
| Johnsson, E | 1 |
| Garcia-Sanchez, R | 1 |
| Kurlyandskaya, R | 1 |
| Sjöström, CD | 1 |
| Jacob, S | 1 |
| Seufert, J | 1 |
| Dronamraju, N | 1 |
| Csomós, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A 52-Week, Multi-Centre, Randomised, Parallel-Group, Double-Blind, Active Controlled, Phase IV Study to Evaluate the Safety and Efficacy of Dapagliflozin or Dapagliflozin Plus Saxagliptin Compared With Sulphonylurea All Given as Add-on Therapy to Metformi[NCT02471404] | Phase 4 | 939 participants (Actual) | Interventional | 2015-09-21 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Change in FPG from baseline (week 0) to week 52 (NCT02471404)
Timeframe: Baseline, week 52. Values recorded after rescue treatment or collected more than 8 days after the last dose date were excluded from the analysis
| Intervention | FPG (mmol/L) (Least Squares Mean) |
|---|---|
| Dapaglifozin 10mg | -1.62 |
| Saxagliptin 5mg and Dapagliflozin 10mg | -2.08 |
| Glimepiride 1mg/2mg/4mg | -1.49 |
Change in HbA1c from baseline (week 0) to week 52. (NCT02471404)
Timeframe: Baseline, week 52. Values recorded after rescue treatment or collected more than 8 days after the last dose date were excluded from the analysis
| Intervention | HbA1c % (Least Squares Mean) |
|---|---|
| Dapaglifozin 10mg | -0.82 |
| Saxagliptin 5mg and Dapagliflozin 10mg | -1.2 |
| Glimepiride 1mg/2mg/4mg | -0.99 |
Change in body weight from baseline (week 0) to week 52 (NCT02471404)
Timeframe: Baseline, week 52. Values recorded after rescue treatment or collected more than 8 days after the last dose date were excluded from the analysis
| Intervention | Weight (kg) (Least Squares Mean) |
|---|---|
| Dapaglifozin 10mg | -3.54 |
| Saxagliptin 5mg and Dapagliflozin 10mg | -3.15 |
| Glimepiride 1mg/2mg/4mg | 1.76 |
Number (%) of patients rescued. (NCT02471404)
Timeframe: Over the 52 week treatment period
| Intervention | Percentage of participants (Number) |
|---|---|
| Dapaglifozin 10mg | 18.6 |
| Saxagliptin 5mg and Dapagliflozin 10mg | 8.3 |
| Glimepiride 1mg/2mg/4mg | 21.4 |
Percentage of patients reporting at least 1 episode of hypoglycaemia (symptomatic + blood glucose <=50 mg/dL) during the double-blind treatment period (NCT02471404)
Timeframe: Up to Week 52. Values recorded after rescue treatment or collected more than 8 days after the last dose date were excluded from the analysis
| Intervention | Percentage of participants (Number) |
|---|---|
| Dapaglifozin 10mg | 0 |
| Saxagliptin 5mg and Dapagliflozin 10mg | 0.32 |
| Glimepiride 1mg/2mg/4mg | 4.21 |
The time to rescue (from first dose date after randomisation to start of rescue medication or discontinuation due to lack of glycaemic control) during the 52 week double blind treatment period (NCT02471404)
Timeframe: Over the 52 week treatment period
| Intervention | Weeks (Median) |
|---|---|
| Dapaglifozin 10mg | NA |
| Saxagliptin 5mg and Dapagliflozin 10mg | NA |
| Glimepiride 1mg/2mg/4mg | NA |
1 trial available for glimepiride and Urinary Tract Infections
| Article | Year |
|---|---|
Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add-on to metformin in patients with type 2 diabetes.
Topics: Adamantane; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; | 2018 |